Genmab
Genmab is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly, and (via ProfoundBio) rinatabart sesutecan.
Tisotumab vedotin, epcoritamab (CD20×CD3), rinatabart sesutecan (FRα ADC, phase 3), acasunlimab (PD-L1×4-1BB). DuoBody technology underlies teclistamab, talquetamab, amivantamab.
Tisotumab vedotin is an ADC against tissue factor, the first to show a survival benefit in recurrent cervical cancer.
The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing.
Epcoritamab is an under-the-skin injection that pulls T cells onto lymphoma cells; it is approved for relapsed large B-cell and follicular lymphoma, and moving toward first line.
A two-armed antibody that blocks EGFR while gripping LGR5, a marker of cancer stem cells, so it hits the cells that regrow tumours.
Rinatabart sesutecan is a next-generation folate-receptor ADC with a topoisomerase payload that responds in both ovarian and endometrial cancer regardless of receptor level.
Pages like this
not linked directly; found by shared links- CompanyMerus
Shares LiGeR-HN1, Petosemtamab, Head and neck squamous cell carcinoma.
- TermLGR5
Shares LiGeR-HN1, Petosemtamab, Head and neck squamous cell carcinoma.
- PairingEGFR-directed bispecific + PD-1 blockade
Shares LiGeR-HN1, Petosemtamab, Head and neck squamous cell carcinoma.
- InstitutionTongji Hospital, Huazhong University of Science and Technology
Shares Endometrial cancer, Cervical cancer, Ovarian cancer, Diffuse large B-cell lymphoma.
- TrialEPCORE DLBCL-2
Shares Epcoritamab, Diffuse large B-cell lymphoma.
- TargetFolate receptor alpha
Shares RAINFOL-01 (Rina-S), Rinatabart sesutecan, Endometrial cancer, Ovarian cancer.
- TrialinnovaTV 301 / ENGOT-cx12 / GOG-3057
Shares Tisotumab vedotin, Cervical cancer.
- TrialEPCORE DLBCL-1
Shares Epcoritamab, Diffuse large B-cell lymphoma.